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Abstract
The aim of this study was to prepare biodegradable sustained release magnetite microspheres sized
between 1 to 2 μm. The microspheres with or without magnetic materials were prepared by a W/
O/W double emulsion solvent evaporation technique using poly(lactide-co-glycolide) (PLGA) as
the biodegradable matrix forming polymer. Effects of manufacturing and formulation variables on
particle size were investigated with non-magnetic microspheres. Microsphere size could be
controlled by modification of homogenization speed, PLGA concentration in the oil phase, oil phase
volume, solvent composition, and polyvinyl alcohol (PVA) concentration in the outer water phase.
Most influential were the agitation velocity and all parameters that influence the kinematic viscosity
of oil and outer water phase, specifically the type and concentration of the oil phase. The magnetic
component yielding homogeneous magnetic microspheres consisted of magnetite nanoparticles of
8 nm diameter stabilized with a polyethylene glycole/polyacrylic acid (PEG/PAA) coating and a
saturation magnetization of 47.8 emu/g. Non-magnetic and magnetic microspheres had very similar
size, morphology, and size distribution, as shown by scanning electron microscopy. The optimized
conditions yielded microspheres with 13.7 weight% of magnetite and an average diameter of 1.37
μm. Such biodegradable magnetic microspheres seem appropriate for vascular administration
followed by magnetic drug targeting.
Background
Controlled release parenteral nanospheres and micro-
spheres made from biodegradable polymers such as poly
(lactide-co-glycolide) (PLGA) have been widely investi-
gated for a variety of therapeutic agents. PLGA polymers
have an excellent record of biocompatibility, biodegrada-
bility and non-immunogenicity [1-3]. PLGA polymers
have also been used in the preparation of controlled
release delivery systems, such as Lupron Depot® (TAP
Pharmaceutical Product Inc.), Zoladex™ (Zeneca),
Decapeptyl™ (Ipsen Biotech), and Prostap SR™ (Lederle),
all of which are licensed for intramuscular use in humans
in both Europe and the U.S.A.
Functionalized magnetic nanospheres and microspheres
(MMS) are usually formulated by encapsulation of mag-
netic nanoparticles (e.g., magnetite) into the biodegrada-
ble polymeric matrix and are being used evermore for
biomedical applications including drug delivery, diagnos-
tic magnetic resonance imaging (MRI), magnetic cell sep-
aration, tissue repair, hyperthermia and magnetofection
[4-8]. Superparamagnetic iron oxide contrast agents have
been approved by FDA for MRI. Commercial iron oxide
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nanoparticles of maghemite (Endorem® and Resovist®) are
used as contrast agents in MRI for the diagnosis and exact
location determination of brain [9,10] and cardiac inf-
arcts [11], and for the detection of liver lesions and
tumors [12], where the magnetic nanoparticles tend to
accumulate at higher levels due to the difference in tissue
composition and/or endocytotic uptake processes. In a
clinical study, it was concluded that intracranial thermo-
therapy using magnetic nanoparticles can be safely
applied on glioblastoma multiforme patients [13]. The
toxicity of magnetite encapsulated in PLGA has not been
tested, although PLA microspheres containing 10% mag-
netite were tested in a rat model for treatment of intraspi-
nal glioblastoma by delivering local radiation. After
injection of 0.5 mg of microspheres through an intrathe-
cal catheter, all 12 rats survived for 15 months with no
apparent side effects or weight loss [14]. Due to their mag-
netic component, MMS can be locally targeted using exter-
nally applied magnetic fields. A promising approach, for
example, is the intravascular injection of magnetic parti-
cles (ferrofluids) bound to anticancer agents that are then
concentrated in the desired area (e.g., a tumor) by an
external magnetic field [15]. It might thus be possible to
overcome the systemic side effects of many chemothera-
peutic agents.
We sought to develop biodegradable sustained release
PLGA MMS which could be administered by intravascular
injection and which are attracted by external magnetic
fields to a specific site [6]. For the desired mode of admin-
istration, the size of the MMS must be optimized. The
MMS have to be smaller than red blood cells and must be
delivered through blood vessels at concentrations which
do not embolize (clog) the capillaries. Since the diameter
of the smallest blood vessels, the capillaries, is typically 7–
8 μm [16], a particle size under 2 μm enables intravascular
injection and is also desirable for intramuscular and sub-
cutaneous administration, minimizing possible irritant
reactions [17]. On the non-physiological side, particle size
also influences both the loading efficiency of the magnetic
materials that turn microspheres into MMS and of the
therapeutic agents. This is especially important if the load-
ing efficiencies have to be maximized. In general, the
larger the particle size, the higher the encapsulation effi-
ciency for drugs and magnetic nanoparticles, as can be
explained by the fact that the size increase is related to a
relative decrease of the surface area, thus reducing the pos-
sibility of drug loss by diffusion during the fabrication
procedure [17]. In addition, the magnetic forces required
to direct and localize the MMS will increase substantially
with decreasing particle size, requiring that the micro-
spheres be large enough to allow the use of reasonably
sized magnets [18].
Our work focuses on the effect of process and formulation
variables in the preparation of magnetic PLGA micro-
spheres in the specific size range of 1 to 2 μm. A couple of
papers describe the use of large PLGA MMS of 20–50 μm
[19,20], while Lee et al. prepared magnetic PLGA nano-
particles (90–180 nm) by an emulsification-diffusion
method after stabilizing iron oxide nanoparticles by
sodium oleate and sodium dodecylbenzenesulfonate
[21]. Most recently, Liu et al. have successfully fabricated
microspheres containing 45 weight% of oleic acid-coated
magnetite using a polymer mixture of PLGA and a diblock
copolymer of poly(lactic acid) and polyethylene glycol
(PLA-PEG). They used a single emulsion method and
loaded the magnetite into the oil phase [22]. To our
knowledge, there are no other studies looking at small
PLGA MMS of 1–2 μm. In the field of non-magnetic
microspheres, however, Muramatsu et al. have prepared
uniform PLGA microspheres by forcing the polymer dis-
solved in methylene chloride through a glass membrane
of homogeneous pore size of about 1120 nm [23]. Two
other studies examined the preparation conditions of
PLA, PLGA and PLA-PEG-PLA particles incorporating
DNA, in the size range of 200–700 nm [24] and 1–2 μm
[25]. Still another method of preparing PLGA micro-
spheres is acoustic excitation, resulting in over 95% of the
spheres having a diameter of 1.0–1.5 μm [26]. But none
of these preparations involved the incorporation of mag-
netic materials.
In the present investigation, both non-magnetic and mag-
netic microspheres were prepared by a W/O/W double
emulsion and solvent evaporation method. Effects of
homogenization conditions (speed and time), inner
water phase (volume and protein concentration), oil
phase (volume, polymer concentration in oil phase and
solvent composition), outer water phase (stabilizer con-
centration) and evaporation speed on particle size were
systematically investigated. The size optimized method
found during the preparation of non-magnetic micro-
spheres was then applied to the making of MMS by load-
ing water dispersible magnetite coated by polyethylene
glycole/polyacrylic acid (PEG/PAA) into the inner water
phase.
Materials and methods
Materials
PLGA (Lactel® biodegradable polymers) having a lactide/
glycolide molar ratio of 85:15 with an intrinsic viscosity of
0.61 dl/g and an average MW of 23,878 (measured by size
exclusion chromatography using polystyrene standards)
was purchased from Durect Co., U.S.A. Polyvinyl alcohol
(PVA, 87~89% hydrolyzed, MW 13,000~23,000) and
bovine serum albumin (BSA) were bought from Sigma.
Magnetite coated by PEG/PAA (about 8 nm diameter, as
can be seen in the sixth figure of results and discussionBioMagnetic Research and Technology 2007, 5:2 http://www.biomagres.com/content/5/1/2
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part) was kindly donated by Materials Modification Inc.,
U.S.A. Dichloromethane (DCM) and ethyl acetate (EA)
were of analytical grade and were purchased from Fisher.
Preparation of Microspheres
Microspheres were fabricated using a water-in-oil-in-water
(w/o/w) double emulsion solvent evaporation method.
The optimized method consisted of adding 0.2 ml of a 1
mg/ml BSA solution to a 4 ml mixture of DCM and EA at
a ratio of 3 to 1 containing 200 mg of PLGA. A first w/o
emulsion was prepared using a homogenizer (Polytron
PT10-35; Kinematica, Luzern, Switzerland) in an ice bath
at 26,000 rpm for 2.5 min. Fifteen ml of a 1% PVA solu-
tion was then poured directly into the primary emulsion
and re-emulsified using the same homogenizer under the
same conditions for another 2.5 min. This w/o/w emul-
sion was immediately poured into a beaker containing 85
ml of 1% PVA solution and was stirred in a hood under an
overhead propeller for 2 h, allowing the solvent to evapo-
rate. The solidified microspheres were harvested by cen-
trifugation at 2500 rpm for 10 min and washed with
distilled water three times.
The processing parameters of homogenization (speed and
time), inner water phase (volume and BSA concentra-
tion), oil phase (polymer concentration, volume, solvent
composition), PVA concentration in outer water phase,
and evaporation speed were varied. All trials were run in
triplicate.
To prepare the MMS, water dispersible magnetite with a
PEG/PAA coating was added to the BSA-containing inner
water phase. The same protocol used for the non-mag-
netic case was then followed.
Microsphere and Magnetite Nanoparticle Analysis
After gold-palladium coating, the shape and surface mor-
phology of microspheres and MMS were examined using
scanning electron microscopy (SEM) (Hitachi S-4500,
Tokyo, Japan). To determine the size and morphology of
the magnetic nanoparticles, a drop of an aqueous disper-
sion of magnetite nanoparticles was placed on a formvar-
coated copper transmission electron microscopy (TEM)
grid (150 mesh, Ted Pella Inc. Redding, CA) and allowed
to air-dry.
The zeta potential of the magnetite nanoparticles was
determined in a Zetasizer (Malvern Instruments, Malvern,
UK) and their magnetic properties on a vibrating sample
magnetometer (VSM) (Model 155, Princeton Applied
Research).
The microspheres were sized by laser diffraction using a
Mastersizer 2000 and the dispersing unit Hydro 2000 MU
(Malvern Instruments, Malvern, UK). The average particle
size and standard deviation was expressed as the volume
mean diameter from 3 different microsphere batches
each.
Determination of Kinematic Viscosity
The kinematic viscosity of PLGA in the DCM/EA (3/1) sol-
vent system and PVA in water of different concentrations
was determined using a capillary tube viscometer (Ubbe-
lohde type, Fisher). This method is based on measuring
the efflux time of a fixed volume of liquid samples
through a capillary tube and then multiplying this time by
the viscometer constant. Three determinations per sample
were carried out at room temperature and mean value and
standard deviation was calculated.
Results and Discussion
Several microencapsulation methods, such as phase sepa-
ration spray-drying and emulsion solvent evaporation
methods (o/w [21], w/o/w [25], w/o/o [27]), have been
developed for the microencapsulation of a wide variety of
drugs [28]. Among them, the water-in-oil-in-water (w/o/
w) double emulsion solvent evaporation method is prob-
ably the most used and has been proven to be advanta-
geous over the single emulsion solvent evaporation
method for the encapsulation of highly water soluble
compounds [29,30]. In the w/o/w process, the water dis-
solvable or water dispersible components such as proteins
and peptides, and other additives are dissolved or dis-
persed in an aqueous solution, which is then emulsified
in an organic solvent containing the dissolved PLGA. This
primary emulsion (w/o) is then dispersed in a second
aqueous phase containing a suitable emulsifier and forms
a double emulsion (w/o/w). Solid microspheres are col-
lected following the complete removal of the volatile
organic phase. All the processing and formulation factors
must be controlled since they influence the stability of the
emulsion and eventually the particle size, surface mor-
phology, loading efficiency and release pattern of the
microspheres [31,32]. In the following text, the influence
of these parameters on making small PLGA microspheres
will be discussed in detail.
Influence of homogenization speed on microsphere size
According to the literature, the effect of homogenization
speed on the size and shape of microspheres is not con-
sistent [21,27,33,34]. In most cases, however, particle size
decreases with increasing homogenization speed. In the
present study, a dramatic decrease of microsphere size
from 3.11 to 1.26 μm occurred when the homogenization
speed in both the primary w/o and final w/o/w emulsion
increased from 11,000 to 30,000 rpm (Figure 1A).
As the homogenization speed increases, the shear stress
increases and the established balance between tangential
stress at the droplet interface impacted by the homoge-BioMagnetic Research and Technology 2007, 5:2 http://www.biomagres.com/content/5/1/2
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nizer and interfacial tension is going to be altered. The
larger tangential stress leads to a reduction in droplet size,
while the homogenization speed affects the relative vis-
cosity of the emulsion. Typically, the viscosity reduction at
a higher rotational speed is responsible for a decrease in
particle size [21]. While homogenization speed was found
to be the dominant factor for the sizing of microspheres,
homogenization times, at least at high homogenization
speeds of 26,000 rpm (Figure 1B) did not significantly
change the final microsphere size.
Influence of inner water phase on microsphere size
An inner water phase volume increase from 0.2 to 0.4 ml
resulted in a small microsphere size increase from 1.34 to
1.51  μm (Figure 2A). However, further increasing the
inner water phase volume from 0.4 to 0.8 ml showed only
negligible size changes. These results are different from
those reported by Crotts et al., who showed that the inner
water phase volume had a significant effect on final
microsphere size [30]. In contrast, their particles were
much larger between 20~300 μm. A large inner water vol-
ume is especially important when larger amounts of
hydrophilic proteins, peptides, or water dispersible com-
ponents such as the magnetic materials applied in this
study need to be encapsulated.
The effect of the protein content, here BSA, in the primary
water phase on microsphere size is shown in Figure 2B.
The size increased from 1.34 to 1.71 μm with the BSA con-
centration increase from 1 to 125 mg/ml, but seemed to
have reached a maximum at this concentration, as further
increases to 250 mg/ml showed no significant changes.
Proteins must maintain their intact three-dimensional
structure and their chemical integrity during the encapsu-
lation process to allow for delivery of the native protein
upon administration. Preparing PLGA microspheres can
cause physical and chemical degradation of the to-be-
encapsulated protein; therefore the formulation of potent
therapeutic proteins into microspheres often requires the
use of a carrier protein as a diluent, protective agent and
enhancer of encapsulation efficiency. Several stabilization
methods have been attempted with variable success.
These methods include maximizing the protein concen-
tration in solution, adding a metal (e.g., zinc), adding an
additional carrier protein (e.g., albumin), adding a small
osmolyte such as trehalose or mannitol, or adding a gel-
ling agent such as gelatin, carboxymethyl cellulose
sodium, Arabic gum, or alginate sodium [25,35-37]. In
some manufacturing processes, the addition of albumin
aided in protecting growth factors from denaturation in
organic solvents [38,39]. Our results indicate that BSA has
the potential of stabilizing other protein or peptide drugs
without significantly changing the size and size distribu-
tion of microspheres.
Influence of oil phase on microsphere size
The polymer concentration in the oil phase affects the
microsphere size and loading efficiency as well as the
release profiles of pharmacological active agents. We
found that the size of microspheres increased from 1.16 to
1.74 μm with an increase in PLGA concentration from 2.5
to 7.5% (w/v) in the oil phase (Figure 3A). These results
agree with earlier findings using a similar method for the
preparation of nanospheres sized 120–180 nm [17,21],
Effect of (A) inner water phase volume and (B) BSA concen- tration in inner water phase on average microsphere diame- ter Figure 2
Effect of (A) inner water phase volume and (B) BSA concen-
tration in inner water phase on average microsphere diame-
ter.
Effect of (A) homogenization speed and (B) time on average  microsphere diameter Figure 1
Effect of (A) homogenization speed and (B) time on average 
microsphere diameter.BioMagnetic Research and Technology 2007, 5:2 http://www.biomagres.com/content/5/1/2
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microspheres sized 1–3 μm [25], microspheres sized 20–
50 μm [40], and even larger microspheres sized 30–210
μm [41]. The increase of PLGA concentrations parallels
the viscosity increase of the polymer dissolved in the
DCM/EA (3/1) mixture (Figure 3A). The higher the viscos-
ity of the oil phase, the higher the forces that need to be
overcome to form fine particles. Highly viscous polymer
solutions have been reported to produce microspheres
with a dense core, which in turn show decreased initial
protein burst release [42]. Furthermore, the viscosity of
the polymer solution affects other microsphere properties
such as drug content, specific surface area, and porosity,
due to its effect on the rate of solvent extraction. The vis-
cosity characterization is thus an important part of the
microsphere process development [43].
The effect of oil phase volume on microsphere size was
studied by keeping the amount of PLGA constant and
increasing the volume of the oil phase from 3.0 to 6.0 ml.
The size of microspheres dropped from 1.78 to 1.21 μm
(Figure 3B). This may be due to the fact that an increase in
the volume of the oil phase generates a less viscous oil
phase, from which droplets break off more easily into
smaller droplets, thus generating smaller microspheres.
The efficiency of encapsulation and the physicochemical
properties of microspheres depend to a great extent on the
interactions between polymer, drug and solvent. The com-
position of solvent, including the DCM and EA used here,
affect the size, morphology and in vitro release profiles
due to the speed of polymer precipitation at the polymer/
solvent interface [19]. During microsphere preparation,
protein molecules are exposed to unfavorable factors.
Organic solvents can easily cause aggregation and destabi-
lize the high-grade structure of protein molecules. It is
reported that the addition of less toxic EA can result in an
increase of glucose oxidase activity in PLA-PEG micro-
spheres, suggesting that EA is a more suitable solvent to
preserve the protein activity during microsphere prepara-
tion than DCM [37]. For these reasons, we investigated
various volume ratios of DCM to EA in the oil phase. The
microsphere size increased linearly from 0.78 to 1.56 μm
when the percentage of DCM in the mixture increased
from 25 to 100% (Figure 4). This may be due to the slower
precipitation of the polymer at the particle surface since
DCM is less soluble in water and thus diffuses more
slowly than EA into the surrounding water phase [44].
However, when pure EA was used as the oil phase a very
wide standard deviation was obtained (Figure 4). Presatu-
rating the inner water phase with EA, which was expected
to allow for a more defined emulsion preparation, did not
improve the size distribution (not shown). Many of the
microspheres were distorted and oval in shape. This might
be due to a much faster precipitation time of the polymer
Effect of DCM content in DCM/EA on average microsphere  diameter Figure 4
Effect of DCM content in DCM/EA on average microsphere 
diameter.
Effect of formulation variables in oil phase Figure 3
Effect of formulation variables in oil phase. (A) Effect of 
PLGA concentration in oil phase on average microsphere 
diameter (▪, y-axis is to the left) and the relationship between 
PLGA concentration and kinematic viscosity (❍, y-axis is to 
the right). (B) Effect of oil phase volume on average micro-
sphere diameter (▲, y-axis is to the right).BioMagnetic Research and Technology 2007, 5:2 http://www.biomagres.com/content/5/1/2
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at the polymer/solvent interface because of EA's lower
boiling point and higher water solubility (about 10%).
Thus the composition of the solvent plays a key role in the
formation of microspheres and affects the solidification
time and size of the microspheres [27].
Influence of PVA concentration and evaporation speed on 
microsphere size
A wide range of substances, such as PVA, methyl cellulose,
sorbitan monooleate (spans), sodium alginate, gelatin,
and sodium dodecyl sulfate, have been used for the stabi-
lization of polymeric microspheres produced by emulsion
solvent evaporation techniques [29,45,46]. In this study,
PVA was used as the stabilizing and emulsifying agent.
When the concentration of PVA was varied from 0.5 and
2% (w/v), the microsphere size decreased (Figure 5A). The
effect was probably mainly due to the increasing viscosity
of the PVA solution (Figure 5A). During the emulsion for-
mation, the droplets get smaller and smaller under the
strong shear stress, while the droplets tend to coalesce
again to reduce their surface energy. The presence of sur-
factant molecules can stabilize the emulsion by forming a
protective layer around the droplets thus impeding drop-
let coalescence and coagulation. Important properties of
the emulsifying agent for optimal stabilization of the
droplets during microencapsulation are a) a high surface
activity (interfacial tension <10 dyn/cm), b) a high viscos-
ity in the external phase, c) an adequate electrical charge,
and d) the existence of a film adsorbed on the droplet sur-
face [47]. A good example of choosing these properties
correctly is given by Lin et al. who reported that a 1% PVA
solution had low interfacial tension towards DCM of ~1.8
dyn/cm and formed a multimolecular film, resulting in
better microsphere uniformity [46].
The stabilizer PVA must also be present during the final
droplet hardening process, the solvent extraction and
evaporation step in order to guarantee a narrow size dis-
tribution. The stirring speed at this point, however, does
not seem to affect the final microsphere size (Figure 5B).
Comparison of non-magnetic and magnetic microspheres
Since all optimizations were performed on empty PLGA
microspheres, we needed to investigate whether the addi-
tion of the magnetic component would alter the size and
size distribution of the final MMS. For this purpose we
prepared MMS by adding the water dispersible magnetite
nanoparticles shown in Figure 6A to the inner water
phase. These magnetite (Fe3O4) particles were of relatively
homogeneous size with an average diameter of 8 nm. The
magnetization curve in Figure 6B shows that the nanopar-
ticles measured as air-dried powder were superparamag-
netic and had a saturation magnetization of 47.8 emu/g.
To counteract hydrophobic interactions between parti-
cles, including agglomeration, large cluster formation,
and strong magnetic dipole-dipole attractions and to sta-
bilize the magnetite nanoparticles, their surface was
coated with 6% PEG/PAA. This coating gave the nanopar-
ticles a zeta potential of -34.1 mV and likely helped in sta-
bilization of the suspension and in incorporation of the
nanoparticles into the microsphere matrix.
Using the optimized conditions found for the non-mag-
netic microspheres, magnetite microspheres were pre-
pared that contained 13.7 weight% of the magnetite
nanoparticles. With a d50 size of 1.37 μm, these MMS were
statistically indistinguishable from the non-magnetic
microspheres with a d50 of 1.23 μm. Their size distribu-
tions given in Figure 7 were also very close and as narrow
as needed for future in vivo applications. SEM pictures
(Figure 8) confirm that the size and surface morphology
of microspheres were not changed by adding magnetite to
the formulation. In combination with information from
TEM pictures, it is possible to confirm that the magnetic
nanoparticles are dispersed well inside the MMS (Figure
9B). Furthermore, the jagged edges seen by TEM are not
seen in the SEM, which means that the magnetic nanopar-
(A) Effect of PVA concentration on average microsphere  diameter (▪, y-axis is to the left) and its relationship with the  kinematic viscosity (❍, y-axis is to the right) Figure 5
(A) Effect of PVA concentration on average microsphere 
diameter (▪, y-axis is to the left) and its relationship with the 
kinematic viscosity (❍, y-axis is to the right). (B) Effect of 
evaporation speed on average microsphere diameter (▲, y-
axis is to the right).BioMagnetic Research and Technology 2007, 5:2 http://www.biomagres.com/content/5/1/2
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Properties of magnetite nanoparticles with PEG/PAA coating Figure 6
Properties of magnetite nanoparticles with PEG/PAA coating. (A) TEM. (B) Magnetization curve.
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C. Volume and number size distribution of (A) PLGA microspheres and (B) MMS formulated with PEG/PAA coated magnetite Figure 7
C. Volume and number size distribution of (A) PLGA microspheres and (B) MMS formulated with PEG/PAA coated magnetite.
0.1 1 10
0
5
10
15
20
25
D
i
s
t
r
i
b
u
t
i
o
n
 
(
%
)
Particle size (µm)
 Number
 Volume A
0.1 1 10
0
5
10
15
20
25
D
i
s
t
r
i
b
u
t
i
o
n
 
(
%
)
Particle size (µm)
 Number
 Volume BBioMagnetic Research and Technology 2007, 5:2 http://www.biomagres.com/content/5/1/2
Page 9 of 11
(page number not for citation purposes)
SEM picture of (A) PLGA microspheres and (B) MMS Figure 8
SEM picture of (A) PLGA microspheres and (B) MMS.BioMagnetic Research and Technology 2007, 5:2 http://www.biomagres.com/content/5/1/2
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ticles are embedded well by the microspheres' matrix
material PLGA.
Conclusion
Our experiments showed that the size of biodegradable
PLGA microspheres can be controlled by modifying the
process and formulation variables, in particular the agita-
tion velocity and the parameters that influence the kine-
matic viscosity of both the oil phase and outer water
phase, such as the type and concentration of the oil phase.
In addition, the preparation of magnetic PLGA micro-
spheres using the same optimized conditions yielded very
similar microspheres in regards of size, size distribution
and surface structure. It is important, however, that the
magnetic component is stabilized and mixes well with the
phase to which it is added. Using nanomagnetite particles
coated with PAA/PEG complied with these conditions
and did not seem to change the final microsphere proper-
ties at all. Such MMS of 1~2 μm have the potential to serve
as controlled released drug delivery carriers for intravascu-
lar applications, specifically for magnetic targeting of dif-
ferent therapeutic agents with the help of external
magnetic fields [6]. Although the encapsulation of phar-
macologically active drugs into the PLGA MMS was not
investigated in this study, it is expected that highly potent
protein or peptide drugs that require dosing in the nano-
and microgram amounts will influence size and size dis-
tribution of the final microspheres only in a minor way.
This is based on the fact that the encapsulation of the pro-
tein BSA over a wide concentration range did not alter the
size of the final microspheres in this study.
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